Email Facebook Twitter

London South East - Oil & Gas Investor Evening: Malcy, Echo, Savannah, SDX
Paul Welch speaks at London South East's Oil & Gas Investor Evening

Premaitha Share Price (NIPT)

Share Price Information for Premaitha (NIPT)

Share Price: 8.60Bid: 8.50Ask: 8.70Change: 0.00 (0.00%)No Movement on Premaitha
Spread: 0.20Spread as %: 2.35%Open: 8.90High: 8.90Low: 8.45Yesterday’s Close: 8.60

Premaitha Health Plc Ord 0.1P

Premaitha is listed in the FTSE AIM All-Share
Premaitha is part of the Medicine and Biotech Research sector

Share Price SpacerPrice
Share Price SpacerBid
Share Price SpacerAsk
Share Price SpacerChange
Share Price SpacerVolume
Share Price SpacerOpen
Share Price SpacerHigh
Share Price SpacerLow
Share Price SpacerClose
Share Price SpacerCurrency

Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 396.68m £34.11m 20,000

52 Week High 15.75 52 Week High Date 19-SEP-2018
52 Week Low 3.75 52 Week Low Date 26-MAR-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
19 311,845 66,526 -2.867 -3.00 0.00 0.00

London South East Users info for Premaitha

Trade Prc

Trade Type:

Trade Type:

Trade Type:

View more Premaitha trades >>

Directors Deals for Premaitha (NIPT)
Trade DateActionNotifierPriceCurrencyAmountHolding
Trade Notifier Information for Premaitha Health
Barry Kenneth Hextall held the position of CFO at Premaitha Health at the time of this trade.
 Barry Kenneth Hextall
Trade Notifier Information for Premaitha Health
Bill Chang held the position of Director at Premaitha Health at the time of this trade.
 Bill Chang
Trade Notifier Information for Premaitha Health
Lyn Rees held the position of CEO at Premaitha Health at the time of this trade.
 Lyn Rees
View more Premaitha directors dealings >>

Posts: 5,763
Opinion:No Opinion
Today 22:10
yes, fair points there Hemo.I would have thought that TF must have been in agreement with the settlement in the first place wouldn't they? The way management talk it seems that all is hunky dory but yes, I do get your drift about a conflict of interest so to speak, or is it?
Posts: 390
Opinion:No Opinion
Today 21:45
I am intrigued by the position TF finds itself in and what it’s next play is in this complex saga. I would also like some reassurance on their status in the NIPT market and their intentions regarding Premaitha.

It will no longer have a NIPT foothold in the PPA territories, which it will have to cede to Illumina.

It seems that Premaitha is now platform-agnostic, which suggests to me that in the PPA territories they will sell an Illumina product and outside the PPA territories they will sell either TF or Illumina products according to customer demand. That must irk TF and I am worried we are at risk of alienating them.

There is talk now of a debt for equity swap and even a debt write-off. Where will that lead us? TF could have 20% of the equity .What does it mean? TF could exercise their warrants at an overall price of say 12p and then we use the proceeds to repay the debt but then we have a significant shareholder who could effectively be supporting a major rival if Illumina take most of the business.

I don't think we can keep both TF and Illumina happy and we have to get in bed with one of them wholly. It seems it should have been Illumina from the start but we are where we are and we probably need to split the company in two as has been mentioned previously and work with Ilumina in PPA territories and TF outside. I don't think it would be so much of an issue if TF didn't have so much influence and control over us.

But it needs clarity and resolution because I don't believe the line that we can work with both and everything will be fine with the best of both worlds for Premaitha.
Posts: 282
Opinion:No Opinion
Thermo Fisher
Today 18:54
AR seems to think the debt relief will happen by year end. Hugely positive if they can pull this off
Posts: 2,986
Opinion:No Opinion
RE: Video
Today 10:23
Yes, not definitely needed, required or one hopes significant. What I do assume is it is not ruled out and as I said imv further funding is more likely than not. Thats all i have said and I'm happy with that view in whatever form, timescale and method it comes. I doubt we will generate revenues to make seeking further funding for expansion etc redundant. That's my realistic view. We will see in NEXT financial year and at what higher level we can secure it.The bod consistently paint a rosy view and underperform. I see no reason to expect no requirement for further funds or amend that view as more than likely. Thats all.

Yes, that same consistent bod misjudgement has caused immense frustration and need for bod to recoup some credibility is yet another blow if it means wanting to run with premaitha as the primary strategy rather than seek a TO actively.

Let's wait to see the new strategy, agm news and more one hopes and lets see what debt forgiveness we can secure in on what terms. Atb
Posts: 786
Opinion:No Opinion
RE: Video
Today 09:37
Seems were in danger of losing its perspective once again Twix.

Although I agree that AR didn't rule out funding I don't think he said it was definitely required neither nor imminent nor significant. What he did say was that the stated revenue projections and sp target of Finncap would have to be changed imminently following the AGM, that the debt/equity deal agreed with TMO would clean up the balance sheet and write off debts in process as well as act as cash injection. The net effect of this would be that any further funding would be MINOR, if required, and would come in the NEXT financial year, and be via II's being issued equity directly. As a shareholder I have to be realistic and say that we may have been hoping much for the BoD to publicly commit to never ever undertaking another fundraising but we know at least that if this happens it will be much later on, at higher levels via IIs and would be to support the new 3 year growth plan still to be revealed. That said depending on the growth it could also not be required but at the least I can await till the new growth figures/strategy is issued.

The BoD are what they are. They've consistently called the wrong play when PIs were screaming at them to settle and now want to clear their name rather than go for the obvious play and a quick sale as Sequenom did after their high profile court loss. What's worse if you compare Judge Carr's readings to the RNS issued, media reports and backroom confidences they also had a deliberate policy of misinformation these last years. To support this failed legal strategy the balance sheet was wrecked in process. The constant false reports through back channels have mis-footed me to the detriment of my trading balance here so I share your frustration.

That all said I am hopeful if the strategy outlined in the video did happen that we should be at much higher sp in the next few weeks having (a) debt forgiveness; (b) circa 20% share ownership via TMO through exercise of warrants; (c) new oncology product being supplemented by year end with new reproductive product mentioned in video; (d) new trading statement leading to revised Finncap targets. Other potentials of new 3 year plan, NHS, new contracts will supply further momentum.

I think andy's point of debt forgiveness for the revision of exercisable price of said warrants is also correct FWIW. I think the full 95m shares will be exercised though with the 20,325,204 shares @ 24.6p having their exercisable price revised. I hope that the 74,946,134 shares don't have their exercisable price changed which should mean that the floor of 12p is established and potentially up to £4m of debt is forgiven. This should then give TMO a stake in the company to launch TO down the line or prevent a TO from a 3rd party. That all said I would still be surprised how with the Directors owning 30% of shares and TMO owning 20% how they could not be obligated to make an offer for the rest of company but I'm sure they wil
View more share chat for Premaitha (NIPT) >>

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.